Related Experiment Video
Updated: Aug 5, 2026
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent
1Institute of Molecular Biology, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland.
Abstract:
Replicating adenovirus (Ad) vectors with tumour tissue specificity hold great promise for treatment of cancer. We have recently constructed a conditionally replicating Ad5 AdDeltaEP-TETP inducing tumour regression in a xenograft mouse model. For further improvement of this vector, we introduced four genetic modifications and analysed the viral cytotoxicity in a large panel of melanoma cell lines and patient-derived melanoma cells. (1) The antiapoptotic gene E1B-19 kDa (Delta19 mutant) was deleted increasing the cytolytic activity in 18 of 21 melanoma cells. (2) Introduction of the E1A 122-129 deletion (Delta24 mutant), suggested to attenuate viral replication in cell cycle-arrested cells, did not abrogate this activity and increased the cytolytic activity in two of 21 melanoma cells. (3) We inserted an RGD sequence into the fiber to extend viral tropism to alphav integrin-expressing cells, and (4) swapped the fiber with the Ad35 fiber (F35) enhancing the tropism to malignant melanoma cells expressing CD46. The RGD-fiber modification strongly increased cytolysis in all of the 11 CAR-low melanoma cells. The F35 fiber-chimeric vector boosted the cytotoxicity in nine of 11 cells. Our results show that rational engineering additively enhances the cytolytic potential of Ad vectors, a prerequisite for the development of patient-customized viral therapies.
Insights
Engineered oncolytic adenovirus vectors show enhanced tumor-killing ability. Modifications improved viral cytotoxicity against melanoma cells, paving the way for patient-specific cancer therapies.
Area of Science:
- Oncolytic virotherapy
- Gene therapy for cancer
- Adenovirus vector engineering
Background:
- Replicating adenovirus (Ad) vectors offer potential for cancer treatment through tumor-specific replication.
- A previously developed Ad5 AdDeltaEP-TETP vector demonstrated tumor regression in a xenograft mouse model.
- Further optimization is needed to enhance the efficacy and specificity of these oncolytic vectors.
Purpose of the Study:
- To improve the cytolytic activity and tumor-targeting capabilities of an adenovirus vector.
- To evaluate the impact of specific genetic modifications on viral cytotoxicity in melanoma cell lines.
- To assess the potential for developing patient-customized viral therapies.
Main Methods:
- Deletion of the antiapoptotic E1B-19 kDa gene (Delta19 mutant) to increase cytolysis.
- Introduction of the E1A 122-129 deletion (Delta24 mutant) to modulate replication in cell cycle-arrested cells.
- Modification of the viral fiber with an RGD sequence or the Ad35 fiber (F35) to alter tropism and enhance cell binding (alphav integrins and CD46).
Main Results:
- The Delta19 mutation increased cytolytic activity in 18 of 21 melanoma cells.
- The Delta24 mutation did not abolish activity and enhanced cytolysis in 2 of 21 cells.
- RGD-fiber modification significantly increased cytolysis in all tested CAR-low melanoma cells, while F35 fiber enhanced cytotoxicity in 9 of 11 cells.
Conclusions:
- Rational genetic engineering of adenovirus vectors additively enhances their cytolytic potential against melanoma.
- Modifications targeting viral tropism and apoptosis evasion are crucial for improving oncolytic efficacy.
- These enhanced adenovirus vectors represent a promising foundation for developing personalized viral therapies for cancer patients.
Related Concept Videos
02:23Abnormal Proliferation
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...